Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Virology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Vaccines and Antiviral Agents

Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

Danilo R. Casimiro, Ling Chen, Tong-Ming Fu, Robert K. Evans, Michael J. Caulfield, Mary-Ellen Davies, Aimin Tang, Minchun Chen, Lingyi Huang, Virginia Harris, Daniel C. Freed, Keith A. Wilson, Sheri Dubey, De-Min Zhu, Denise Nawrocki, Henryk Mach, Robert Troutman, Lynne Isopi, Donna Williams, William Hurni, Zheng Xu, Jeffrey G. Smith, Su Wang, Xu Liu, Liming Guan, Romnie Long, Wendy Trigona, Gwendolyn J. Heidecker, Helen C. Perry, Natasha Persaud, Timothy J. Toner, Qin Su, Xiaoping Liang, Rima Youil, Michael Chastain, Andrew J. Bett, David B. Volkin, Emilio A. Emini, John W. Shiver
Danilo R. Casimiro
1Departments of Viral Vaccine Research
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: danilo_casimiro@merck.com
Ling Chen
1Departments of Viral Vaccine Research
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tong-Ming Fu
1Departments of Viral Vaccine Research
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert K. Evans
2Vaccine Pharmaceutical Research and Development
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J. Caulfield
3Virus and Cell Biology, Merck Research Laboratories, Merck and Company, West Point, Pennsylvania 19486
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary-Ellen Davies
1Departments of Viral Vaccine Research
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aimin Tang
1Departments of Viral Vaccine Research
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Minchun Chen
1Departments of Viral Vaccine Research
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lingyi Huang
1Departments of Viral Vaccine Research
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Virginia Harris
1Departments of Viral Vaccine Research
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel C. Freed
1Departments of Viral Vaccine Research
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keith A. Wilson
1Departments of Viral Vaccine Research
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sheri Dubey
1Departments of Viral Vaccine Research
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
De-Min Zhu
2Vaccine Pharmaceutical Research and Development
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Denise Nawrocki
2Vaccine Pharmaceutical Research and Development
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henryk Mach
2Vaccine Pharmaceutical Research and Development
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Troutman
2Vaccine Pharmaceutical Research and Development
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lynne Isopi
2Vaccine Pharmaceutical Research and Development
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donna Williams
2Vaccine Pharmaceutical Research and Development
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Hurni
3Virus and Cell Biology, Merck Research Laboratories, Merck and Company, West Point, Pennsylvania 19486
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zheng Xu
1Departments of Viral Vaccine Research
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey G. Smith
3Virus and Cell Biology, Merck Research Laboratories, Merck and Company, West Point, Pennsylvania 19486
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Su Wang
3Virus and Cell Biology, Merck Research Laboratories, Merck and Company, West Point, Pennsylvania 19486
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xu Liu
3Virus and Cell Biology, Merck Research Laboratories, Merck and Company, West Point, Pennsylvania 19486
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liming Guan
1Departments of Viral Vaccine Research
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Romnie Long
1Departments of Viral Vaccine Research
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wendy Trigona
1Departments of Viral Vaccine Research
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gwendolyn J. Heidecker
1Departments of Viral Vaccine Research
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helen C. Perry
1Departments of Viral Vaccine Research
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natasha Persaud
1Departments of Viral Vaccine Research
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy J. Toner
1Departments of Viral Vaccine Research
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qin Su
1Departments of Viral Vaccine Research
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaoping Liang
1Departments of Viral Vaccine Research
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rima Youil
1Departments of Viral Vaccine Research
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Chastain
1Departments of Viral Vaccine Research
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew J. Bett
1Departments of Viral Vaccine Research
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David B. Volkin
1Departments of Viral Vaccine Research
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emilio A. Emini
1Departments of Viral Vaccine Research
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John W. Shiver
1Departments of Viral Vaccine Research
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/JVI.77.11.6305-6313.2003
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • FIG. 1.
    • Open in new tab
    • Download powerpoint
    FIG. 1.

    Frequencies of Gag-specific IFN-γ-secreting cells from monkeys immunized with Ad5-gag. These values are expressed as the number of SFC per 106 PBMCs. Naïve monkeys (adenovirus type 5 neutralization (neut) titers < 10) were immunized with various doses of Ad5-gag at weeks 0 and 24. Monkeys that were pretreated with one or three 1010 viral particle (vp) doses of non-Gag-encoding adenovirus type 5 virus (producing neutralization titers of ≈30 to 90 and ≈270 to 810, respectively, at the time of the first Ad5-gag injection) were immunized with 1011 viral particles of Ad5-gag at weeks 0 and 24. PBMCs collected at weeks 0, 4, 24, and 28 were incubated in the absence (mock) or presence of the HIV-1 Gag peptide pool, and the mock-corrected response levels are shown here for each monkey. Mock-treated background responses averaged 3 SFC per 106 PBMCs (standard deviation, ≈5 SFC per 106 PBMCs).

  • FIG. 2.
    • Open in new tab
    • Download powerpoint
    FIG. 2.

    CTL responses in monkeys immunized with Ad5-gag. Peptide-pulsed autologous BLCLs were used as target cells at the indicated effector-to-target cell (E:T) ratios, treated with PBMCs (collected at week 8) from Ad5-gag vaccinees restimulated for 2 weeks with gag-expressing vaccinia virus. The percentages of lysed target cells are shown for unpulsed cells (open squares) and cells pulsed with the HIV-1 Gag peptide pool (solid diamonds).

  • FIG. 3.
    • Open in new tab
    • Download powerpoint
    FIG. 3.

    Time course of induction of Gag-specific T-cell responses from PBMCs of representative monkeys that received 1011 viral particles and 109 viral particles of Ad5-gag at week 0 and week 24 (A). Mock responses were subtracted to give the reported levels shown here. Kinetics of induction of p24-specific antibodies as a function of the Ad5-gag dose and adenovirus type 5 preexposure (B). The geometric mean titers (GMT) are shown with standard errors for each cohort of either three or six monkeys. Each curve is defined by the Ad5-gag dose (viral particles, vp) and adenovirus type 5 neutralization titers measured at the start of the immunization. Titers below the dection limit of 10 mMU/ml are scored at 5 mMU/ml (line).

  • FIG. 4.
    • Open in new tab
    • Download powerpoint
    FIG. 4.

    Intracellular IFN-γ staining of PBMCs from Ad5-gag vaccinees following overnight incubation in medium alone (mock) or in medium plus the Gag peptide pool (Gag 20-aa). CD3+ lymphocytes are shown and were characterized for CD8+ staining and IFN-γ production. Numbers reflect the percentage of CD3+ lymphocytes that were CD8+ IFN-γ+ (upper right quadrant) or CD4+ IFN-γ+ (lower right quadrant).

  • FIG. 5.
    • Open in new tab
    • Download powerpoint
    FIG. 5.

    Frequencies of Gag-specific IFN-γ-secreting cells from monkeys immunized with Ad5-gag and MVA-gag. Priming immunizations were administered at weeks 0 and 4, followed by a booster shot at week 24 with the same virus. Shown are the mock-corrected levels against the Gag peptide pool prior to the first dose (pre), 4 weeks after the second dose (post prime), time of the boost (preboost), and 4 weeks after the viral boost (postboost) for each animal.

  • FIG. 6.
    • Open in new tab
    • Download powerpoint
    FIG. 6.

    Frequencies of Gag-specific IFN-γ-secreting cells from PBMCs of macaques immunized following various DNA prime-adenovirus type 5 boost regimens. (A) Macaques were given multiple doses of 5 mg of V1Jns-gag DNA intramuscularly in phosphate-buffered saline, with aluminum phosphate (alum) or with CRL1005 (7.5 mg) at weeks 0, 4, and 8. Shown are levels of antigen-specific T cells (mock corrected) at different time points during and after the priming immunizations. (B) Macaques were treated intramuscularly with three doses (weeks 0, 4, and 8) of 5 mg of V1Jns-gag with and without adjuvants (CRL1005 at 7.5 or 22.5 mg) and boosted with an intramuscular dose of Ad5-gag (107 viral particles or 1011 viral particles) at weeks 24 to 26. Shown are the mock-corrected levels prior to the first dose (pre), 4 weeks after the third dose (post prime), time of the boost (preboost), and 4 weeks after the viral boost (postboost) for each animal.

  • FIG. 7.
    • Open in new tab
    • Download powerpoint
    FIG. 7.

    Intracellular IFN-γ staining of PBMCs from a representative cohort of macaques immunized with three doses of V1jns-gag formulated with CRL1005-based adjuvant (weeks 0, 4, and 8) followed by 107 viral particles of Ad5-gag boost (week 24). Samples were collected at week 10 (postprime) and week 28 (postboost). Shown are CD3+ lymphocytes following incubation with the HIV-1 Gag peptide pool that were characterized for CD8+ staining and IFN-γ production. For all samples, intracellular IFN-γ production in the absence of the peptide pool was minimal (data not shown). Numbers reflect the percentage of CD3+ lymphocytes that were CD8+ IFN-γ+ (upper right quadrant) or CD4+ IFN-γ+ (lower right quadrant) after subtraction of the mock levels.

  • FIG. 8.
    • Open in new tab
    • Download powerpoint
    FIG. 8.

    Percentages of Gag-specific T cells that are CD3+ CD8+ in rhesus macaques immunized with various regimens. The adenovirus type 5 prime-adenovirus type 5 boost (Ad5-Ad5) cohort consisted of animals given two priming doses of the vector (109 or 1011 viral particles) followed by a booster shot of the same dose. The DNA-CRL1005 prime-adenovirus type 5 boost cohort comprised animals given three priming immunizations with 5 mg of V1Jns-gag formulated with CRL1005-based adjuvant, followed by 107 viral particles of Ad5-gag. The percentage values are reported for this cohort of 11 animals before (DNA-CRL1005) and after the boost (DNA-CRL1005-Ad5). The dark diamonds and bars are the cohort arithmetic means and standard errors of the mean, respectively. These data points include those for the animals in Fig. 4 and 7.

PreviousNext
Back to top
Download PDF
Citation Tools
Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene
Danilo R. Casimiro, Ling Chen, Tong-Ming Fu, Robert K. Evans, Michael J. Caulfield, Mary-Ellen Davies, Aimin Tang, Minchun Chen, Lingyi Huang, Virginia Harris, Daniel C. Freed, Keith A. Wilson, Sheri Dubey, De-Min Zhu, Denise Nawrocki, Henryk Mach, Robert Troutman, Lynne Isopi, Donna Williams, William Hurni, Zheng Xu, Jeffrey G. Smith, Su Wang, Xu Liu, Liming Guan, Romnie Long, Wendy Trigona, Gwendolyn J. Heidecker, Helen C. Perry, Natasha Persaud, Timothy J. Toner, Qin Su, Xiaoping Liang, Rima Youil, Michael Chastain, Andrew J. Bett, David B. Volkin, Emilio A. Emini, John W. Shiver
Journal of Virology Jun 2003, 77 (11) 6305-6313; DOI: 10.1128/JVI.77.11.6305-6313.2003

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Virology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene
(Your Name) has forwarded a page to you from Journal of Virology
(Your Name) thought you would be interested in this article in Journal of Virology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene
Danilo R. Casimiro, Ling Chen, Tong-Ming Fu, Robert K. Evans, Michael J. Caulfield, Mary-Ellen Davies, Aimin Tang, Minchun Chen, Lingyi Huang, Virginia Harris, Daniel C. Freed, Keith A. Wilson, Sheri Dubey, De-Min Zhu, Denise Nawrocki, Henryk Mach, Robert Troutman, Lynne Isopi, Donna Williams, William Hurni, Zheng Xu, Jeffrey G. Smith, Su Wang, Xu Liu, Liming Guan, Romnie Long, Wendy Trigona, Gwendolyn J. Heidecker, Helen C. Perry, Natasha Persaud, Timothy J. Toner, Qin Su, Xiaoping Liang, Rima Youil, Michael Chastain, Andrew J. Bett, David B. Volkin, Emilio A. Emini, John W. Shiver
Journal of Virology Jun 2003, 77 (11) 6305-6313; DOI: 10.1128/JVI.77.11.6305-6313.2003
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

AIDS Vaccines
Genes, gag
Genetic Vectors
HIV Infections
Vaccines, DNA

Related Articles

Cited By...

About

  • About JVI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #Jvirology

@ASMicrobiology

       

 

JVI in collaboration with

American Society for Virology

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0022-538X; Online ISSN: 1098-5514